Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
- Conditions
- Delusional DisorderSchizophreniaSchizoaffective Disorder
- Registration Number
- NCT00222807
- Lead Sponsor
- University of Pittsburgh
- Brief Summary
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
- Detailed Description
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association
- Diabetes, type 1 or 2
- Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
- Age above 50 or age below 14
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States